OncoMatch

OncoMatch/Clinical Trials/NCT06701812

Digoxin Medulloblastoma Study

Is NCT06701812 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Digoxin for medulloblastoma.

Phase 2RecruitingH. Lee Moffitt Cancer Center and Research InstituteNCT06701812Data as of May 2026

Treatment: DigoxinThe purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

Min 1 prior line

Must have received: chemotherapy

Patients must have received at least one prior course of chemotherapy for their medulloblastoma

Must have received: irradiation

They must also have received irradiation

Cannot have received: digoxin (digoxin)

Exception: Exposure to digoxin therapy prior to initial diagnosis of medulloblastoma is allowed

Participants taking digoxin for any reason during treatment for initial diagnosis of medulloblastoma or relapse are ineligible. Exposure to digoxin therapy prior to initial diagnosis of medulloblastoma is allowed.

Lab requirements

Blood counts

normal organ and marrow function required

Kidney function

normal organ and marrow function required

Liver function

normal organ and marrow function required

Cardiac function

No evidence of Wolff-Parkinson-White syndrome or high-grade AV block on ECG; no evidence of hypertrophic obstructive cardiomyopathy on echo; no serious or inadequately controlled cardiac arrhythmias

Patients must have normal organ and marrow function. Patient has no evidence of Wolff-Parkinson-White syndrome or high-grade AV block (form of second-degree heart block) on screening ECG. Patient has no evidence of hypertrophic obstructive cardiomyopathy on screening echo. Patients with serious or inadequately controlled cardiac arrhythmias, including baseline ectopy, ventricular tachycardia, frequent premature ventricular contractions (PVCs), or symptomatic sinus bradycardia are excluded from the study.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Alabama at Birmingham Children's of Alabama · Birmingham, Alabama
  • Arkansas Childrens Hospital · Little Rock, Arkansas
  • Connecticut Children's Medical Center · Hartford, Connecticut
  • Children's National Medical Center · Washington D.C., District of Columbia
  • Nemours Jacksonville · Jacksonville, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify